Q3 EPS Forecast for Outlook Therapeutics Boosted by Analyst

Outlook Therapeutics, Inc. (NASDAQ:OTLKFree Report) – Equities research analysts at Brookline Capital Management upped their Q3 2025 EPS estimates for Outlook Therapeutics in a research note issued on Tuesday, May 27th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will earn ($0.29) per share for the quarter, up from their prior forecast of ($0.35). The consensus estimate for Outlook Therapeutics’ current full-year earnings is ($2.27) per share. Brookline Capital Management also issued estimates for Outlook Therapeutics’ Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($1.62) EPS and FY2027 earnings at $0.97 EPS.

Outlook Therapeutics (NASDAQ:OTLKGet Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.15.

Other analysts have also issued reports about the stock. Guggenheim reiterated a “buy” rating on shares of Outlook Therapeutics in a research note on Tuesday, May 20th. HC Wainwright cut their price target on shares of Outlook Therapeutics from $30.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, February 18th. Ascendiant Capital Markets cut their price target on shares of Outlook Therapeutics from $33.00 to $24.00 and set a “buy” rating on the stock in a research note on Monday, February 24th. Finally, Chardan Capital reiterated a “neutral” rating and set a $3.00 price target on shares of Outlook Therapeutics in a research note on Tuesday, February 18th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Outlook Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $10.20.

Read Our Latest Analysis on OTLK

Outlook Therapeutics Price Performance

NASDAQ OTLK opened at $1.85 on Friday. The stock has a market capitalization of $62.10 million, a P/E ratio of -0.25 and a beta of 0.39. The firm’s 50-day moving average is $1.48 and its two-hundred day moving average is $1.90. Outlook Therapeutics has a 12 month low of $0.87 and a 12 month high of $9.25.

Institutional Trading of Outlook Therapeutics

A number of large investors have recently made changes to their positions in OTLK. Rhumbline Advisers increased its stake in shares of Outlook Therapeutics by 1,329.6% during the fourth quarter. Rhumbline Advisers now owns 188,050 shares of the company’s stock worth $355,000 after buying an additional 174,896 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Outlook Therapeutics by 44.8% during the fourth quarter. Bank of New York Mellon Corp now owns 29,764 shares of the company’s stock worth $56,000 after buying an additional 9,211 shares during the period. Commonwealth Equity Services LLC purchased a new stake in shares of Outlook Therapeutics during the fourth quarter worth approximately $48,000. Russell Investments Group Ltd. increased its stake in shares of Outlook Therapeutics by 34,936.7% during the fourth quarter. Russell Investments Group Ltd. now owns 17,168 shares of the company’s stock worth $32,000 after buying an additional 17,119 shares during the period. Finally, Renaissance Technologies LLC purchased a new stake in shares of Outlook Therapeutics during the fourth quarter worth approximately $246,000. 11.20% of the stock is currently owned by hedge funds and other institutional investors.

About Outlook Therapeutics

(Get Free Report)

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.

See Also

Earnings History and Estimates for Outlook Therapeutics (NASDAQ:OTLK)

Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.